A Comparison of Pharmaceutical Product Performance of Albuterol Inhalers Available in the United States and Those Obtained in a Mexican Border Town

Meira Nocella, Emily Kilber, Brittney Witmer, Kelly Karlage, Paul B Myrdal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: American residents travel to Mexico to purchase medications for a fraction of US cost and frequently without prescription requirements. A previous bioequivalence study found differences in lung function measures between 2 brands of Mexican-manufactured albuterol inhalers (both 100 μg/puff). An investigation of the pharmaceutical performance of different inhalers available may illuminate why different clinical results may be observed and offer insight to consumer and provider expectations of such products. Objective: The purpose of this study is to provide some reasonable expectations for a medical tourist who shops in Mexico for albuterol metered dose inhalers (MDIs) or for their health care providers by comparing pharmaceutical product performance of the consumer-available brands. Methods: Five different albuterol MDI products were purchased in Nogales, Mexico. The albuterol content was quantified through high-performance liquid chromatography. The inhalers were analyzed to determine the amount of the albuterol dose that can be considered respirable and compared with the findings from 2 US innovator products. Results: The mean respirable mass for each brand of albuterol MDI was compared with that of the other 4 brands and the 2 US innovator products using Student's t test. All evaluations showed significant differences (P

Original languageEnglish (US)
Pages (from-to)289-295
Number of pages7
JournalJournal of Pharmacy Technology
Volume31
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Albuterol
Nebulizers and Vaporizers
Metered Dose Inhalers
Mexico
Pharmaceutical Preparations
Therapeutic Equivalency
Health Personnel
Prescriptions
High Pressure Liquid Chromatography
Students
Costs and Cost Analysis
Lung

Keywords

  • asthma
  • inhalers
  • international medicine/issues
  • medication safety
  • pharmaceutics
  • β-2-adrenergic agonists

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

A Comparison of Pharmaceutical Product Performance of Albuterol Inhalers Available in the United States and Those Obtained in a Mexican Border Town. / Nocella, Meira; Kilber, Emily; Witmer, Brittney; Karlage, Kelly; Myrdal, Paul B.

In: Journal of Pharmacy Technology, Vol. 31, No. 6, 01.12.2015, p. 289-295.

Research output: Contribution to journalArticle

@article{9893829001c047f6ae225608ff845d53,
title = "A Comparison of Pharmaceutical Product Performance of Albuterol Inhalers Available in the United States and Those Obtained in a Mexican Border Town",
abstract = "Background: American residents travel to Mexico to purchase medications for a fraction of US cost and frequently without prescription requirements. A previous bioequivalence study found differences in lung function measures between 2 brands of Mexican-manufactured albuterol inhalers (both 100 μg/puff). An investigation of the pharmaceutical performance of different inhalers available may illuminate why different clinical results may be observed and offer insight to consumer and provider expectations of such products. Objective: The purpose of this study is to provide some reasonable expectations for a medical tourist who shops in Mexico for albuterol metered dose inhalers (MDIs) or for their health care providers by comparing pharmaceutical product performance of the consumer-available brands. Methods: Five different albuterol MDI products were purchased in Nogales, Mexico. The albuterol content was quantified through high-performance liquid chromatography. The inhalers were analyzed to determine the amount of the albuterol dose that can be considered respirable and compared with the findings from 2 US innovator products. Results: The mean respirable mass for each brand of albuterol MDI was compared with that of the other 4 brands and the 2 US innovator products using Student's t test. All evaluations showed significant differences (P",
keywords = "asthma, inhalers, international medicine/issues, medication safety, pharmaceutics, β-2-adrenergic agonists",
author = "Meira Nocella and Emily Kilber and Brittney Witmer and Kelly Karlage and Myrdal, {Paul B}",
year = "2015",
month = "12",
day = "1",
doi = "10.1177/8755122515595052",
language = "English (US)",
volume = "31",
pages = "289--295",
journal = "Journal of Pharmacy Technology",
issn = "8755-1225",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - A Comparison of Pharmaceutical Product Performance of Albuterol Inhalers Available in the United States and Those Obtained in a Mexican Border Town

AU - Nocella, Meira

AU - Kilber, Emily

AU - Witmer, Brittney

AU - Karlage, Kelly

AU - Myrdal, Paul B

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: American residents travel to Mexico to purchase medications for a fraction of US cost and frequently without prescription requirements. A previous bioequivalence study found differences in lung function measures between 2 brands of Mexican-manufactured albuterol inhalers (both 100 μg/puff). An investigation of the pharmaceutical performance of different inhalers available may illuminate why different clinical results may be observed and offer insight to consumer and provider expectations of such products. Objective: The purpose of this study is to provide some reasonable expectations for a medical tourist who shops in Mexico for albuterol metered dose inhalers (MDIs) or for their health care providers by comparing pharmaceutical product performance of the consumer-available brands. Methods: Five different albuterol MDI products were purchased in Nogales, Mexico. The albuterol content was quantified through high-performance liquid chromatography. The inhalers were analyzed to determine the amount of the albuterol dose that can be considered respirable and compared with the findings from 2 US innovator products. Results: The mean respirable mass for each brand of albuterol MDI was compared with that of the other 4 brands and the 2 US innovator products using Student's t test. All evaluations showed significant differences (P

AB - Background: American residents travel to Mexico to purchase medications for a fraction of US cost and frequently without prescription requirements. A previous bioequivalence study found differences in lung function measures between 2 brands of Mexican-manufactured albuterol inhalers (both 100 μg/puff). An investigation of the pharmaceutical performance of different inhalers available may illuminate why different clinical results may be observed and offer insight to consumer and provider expectations of such products. Objective: The purpose of this study is to provide some reasonable expectations for a medical tourist who shops in Mexico for albuterol metered dose inhalers (MDIs) or for their health care providers by comparing pharmaceutical product performance of the consumer-available brands. Methods: Five different albuterol MDI products were purchased in Nogales, Mexico. The albuterol content was quantified through high-performance liquid chromatography. The inhalers were analyzed to determine the amount of the albuterol dose that can be considered respirable and compared with the findings from 2 US innovator products. Results: The mean respirable mass for each brand of albuterol MDI was compared with that of the other 4 brands and the 2 US innovator products using Student's t test. All evaluations showed significant differences (P

KW - asthma

KW - inhalers

KW - international medicine/issues

KW - medication safety

KW - pharmaceutics

KW - β-2-adrenergic agonists

UR - http://www.scopus.com/inward/record.url?scp=84955254512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955254512&partnerID=8YFLogxK

U2 - 10.1177/8755122515595052

DO - 10.1177/8755122515595052

M3 - Article

AN - SCOPUS:84955254512

VL - 31

SP - 289

EP - 295

JO - Journal of Pharmacy Technology

JF - Journal of Pharmacy Technology

SN - 8755-1225

IS - 6

ER -